Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - 16 Jun 2021 Form 3 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
10%+ Owner
Signature
/s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Issuer symbol
VERV
Transactions as of
16 Jun 2021
Net transactions value
$0
Form type
3
Filing time
16 Jun 2021, 19:18:51 UTC
Next filing
22 Jun 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VERV Series A-2 Preferred Stock 16 Jun 2021 Common Stock 1,343,081 Direct F1
holding VERV Series B Preferred Stock 16 Jun 2021 Common Stock 1,152,490 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series A-2 Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.
F2 The Series B Preferred Stock is convertible into common stock on a 9.2595-for-1 basis into the number of shares of common stock shown in Column 3 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares have no expiration date.